SANA BIOTECHNOLOGY INC (SANA)

Company Profile

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 328 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. The company is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. The company is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. The company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.

Company Info

SANA BIOTECHNOLOGY INC

188 East Blaine Street, Suite 400

Seattle WASHINGTON 98102

P: 12067017914

CEO: Steven D. Harr

Employees: 328

Website: https://sana.com/